Table 1.
Collection of GCTs used for PDX establishment received between March 2016 and March 2019.
| Model | Sample | Site | Stage | Treatmenta | Status at last follow up | Histology patient tumour | Tumour take rate (P0) | Tumour latency time (P0) |
|---|---|---|---|---|---|---|---|---|
| TC1 | Surgery | IV (metastatic disease) | IV (metastatic disease) | Naive | Complete response | Mixed GCT: EC, YSC, TER, seminoma | 3/6 | 12–97 days |
| TC3b | Surgery | Premalignant lesion | Premalignant lesion | N/A | N/A | GCNIS | N/A | N/A |
| TC4 | Biopsy | II (metastatic disease) | II (metastatic disease) | CEB, TIP, TICE, carbo/pacli | Refractory disease | YSC | 1/1 | 21 days |
| TC5 | Surgery | IV (metastatic disease) | IV (metastatic disease) | Naive | Complete response | Mixed GCT: YSC, TER | 5/6 | 15–29 days |
| TC6 | Surgery | II (metastatic disease) | II (metastatic disease) | Naive | Complete response | Mixed GCT: Seminoma, EC, YSC, TER | 0/6 | N/A |
| TC7 | Surgery | I (localized disease) | I (localized disease) | Naive | Complete response | Mixed GCT: EC, seminoma | 0/6 | N/A |
| TC8 | Surgery | IV (metastatic disease) | IV (metastatic disease) | VIP | Complete response | TER | 0/6 | N/A |
| TC10 | Surgery | II (metastatic disease) | II (metastatic disease) | Naive | Complete response | Seminoma | 0/2 | N/A |
GCT germ cell tumour, EC embryonal carcinoma, YSC yolk sac carcinoma, TER teratoma, GCNIS germ cell neoplasia in situ.
CEB carboplatin, etoposide, and bleomycin containing chemotherapy; TIP paclitaxel, ifosfamide and cisplatin containing chemotherapy, VIP etoposide, ifosfamide and cisplatin and etoposide containing chemotherapy, TICE high-dose chemotherapy with stem cell transplant; carbo/pacli: carboplatin and paclitaxel containing chemotherapy.
aTreatment that patient had undergone before tumour tissue was collected for implantation.
bThis tissue material was not included in take rate calculation since it was not a cancer lesion.